| Patent application number | Description | Published |
|---|
| 20090013416 | PDES AS MODIFIERS OF THE IGFR PATHWAYS AND METHODS OF USE - Human PDE genes are identified as modulators of the IGFR pathway and thus are therapeutic targets for disorders associated with defective IGFR function Methods for identifying modulators of IGFR comprising screening for agents that modulate the activity of PDE are provided | 01-08-2009 |
| 20090068186 | MAP3Ks as modifiers of the p53 pathway and methods of use - Human MAP3K genes are identified as modulators of the p53 pathway, and thus are therapeutic targets for disorders associated with defective p53 function. Methods for identifying modulators of p53, comprising screening for agents that modulate the activity of MAP3K are provided. | 03-12-2009 |
| 20090149413 | RORS as Modifiers of the p21 Pathway and Methods of Use - Human ROR genes are identified as modulators of the p21 pathway, and thus are therapeutic targets for disorders associated with defective p21 function. Methods for identifying modulators of p21, comprising screening for agents that modulate the activity of ROR are provided. | 06-11-2009 |
| 20090202563 | C20ORF23 as modifier of the IGFR pathway and methods of use - Human C20ORF23 genes are identified as modulators of the IGFR pathway, and thus are therapeutic targets for disorders associated with defective IGFR function. Methods for identifying modulators of IGFR, comprising screening for agents that modulate the activity of C20ORF23 are provided. | 08-13-2009 |
| 20100159470 | SCDs As Modifiers of the p53 Pathway and Methods of Use - Human SCD genes are identified as modulators of the p53 pathway, and thus are therapeutic targets for disorders associated with defective p53 function. Methods for identifying modulators of p53, comprising screening for agents that modulate the activity of SCD are provided. | 06-24-2010 |
| 20100233164 | COMBINATIONS OF PHOSPHOINOSITIDE 3-KINASE INHIBITOR COMPOUNDS AND CHEMOTHERAPEUTIC AGENTS FOR THE TREATMENT OF HEMATOPOIETIC MALIGNANCIES - Combinations of PI3K inhibitor compounds having Formula I and chemotherapeutic agents, including stereoisomers, geometric isomers, tautomers, metabolites and pharmaceutically acceptable salts thereof, are useful for treating hematopoietic malignancies. Methods of using such combinations for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed. | 09-16-2010 |
| 20110086837 | COMBINATIONS OF A PI3K INHIBITOR AND A MEK INHIBITOR - The invention relates methods of treating a patient with locally advanced or metastatic solid tumors with a combination of an inhibitor of phosphatidylinositol 3-kinase (PI 3-kinase or PI3K) and an inhibitor of mitogen activated protein kinase (MEK) described herein. | 04-14-2011 |
| 20110159508 | GFATS as Modifiers of the P53 Pathway and Methods of Use - Human GFAT genes are identified as modulators of the p53 pathway, and thus are therapeutic targets for disorders associated with defective p53 function. Methods for identifying modulators of p53, comprising screening for agents that modulate the activity of GFAT are provided. | 06-30-2011 |
